Ceftobiprole medocaril sodium not checked
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 3 in the EU
What this is
- How it works
- Cephalosporin Antibacterial FDA class
- How it’s given
- “Ceftobiprole dosing is based on age/body weight and renal function and given at 7.5 mg/kg, 10 mg/kg, or 15 mg/kg (equivalent to 10 mg/kg, 13.3 mg/kg, or 20 mg/kg respectively of ceftobiprole medocaril sodium) q8h, q12h or q24h up to a maximum of 500 mg (equivalent to 667 mg of ceftobiprole medocaril sodium), with all doses infused over 2 hours.”In the company’s words, NCT07929493 on ClinicalTrials.gov
- Tested for
- Staphylococcus Aureus Bacteremia, Endocarditis, Bacterial
- Main trialPhase 3
- “This clinical trial will evaluate the safety, and effectiveness of ceftobiprole compared to standard-of-care antibiotic treatment in children from birth to less than 18 years of age with Staphylococcus aureus bloodstream infection, including right-sided infective endocarditis (IE). The trial will also evaluate the pharmacokinetics of ceftobiprole.”In the company’s words, NCT07929493 on ClinicalTrials.gov
Other drugs for Staphylococcus Aureus Bacteremia
- AZD7760AstraZeneca · Phase 1/2
Coming up1
- 31 Oct 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07929493
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 31 Oct 2028 | A Study of Ceftobiprole Compared With Standard Antibiotic Treatment in Children With Staphylococcus Aureus Bacteremia (SAB) Infection, Including Right-sided Heart Infection | |
| Phase 2Authorised | not given | Osteoarticular infections on equipment: impact of three probabilistic antibiotic therapy strategies on the digestive microbiota and gastrointestinal colonization with multidrug-resistant bacteria | |
| Phase 4Authorised | not given | Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026